Supernus Total Operating Expenses vs Non Operating Income Net Other Analysis
SUPN Stock | USD 28.60 0.17 0.59% |
Supernus Pharmaceuticals financial indicator trend analysis is much more than just breaking down Supernus Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Supernus Pharmaceuticals is a good investment. Please check the relationship between Supernus Pharmaceuticals Total Operating Expenses and its Non Operating Income Net Other accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
Total Operating Expenses vs Non Operating Income Net Other
Total Operating Expenses vs Non Operating Income Net Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Supernus Pharmaceuticals Total Operating Expenses account and Non Operating Income Net Other. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Supernus Pharmaceuticals' Total Operating Expenses and Non Operating Income Net Other is 0.53. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Non Operating Income Net Other in the same time period over historical financial statements of Supernus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Supernus Pharmaceuticals' Total Operating Expenses and Non Operating Income Net Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Supernus Pharmaceuticals are associated (or correlated) with its Non Operating Income Net Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Operating Income Net Other has no effect on the direction of Total Operating Expenses i.e., Supernus Pharmaceuticals' Total Operating Expenses and Non Operating Income Net Other go up and down completely randomly.
Correlation Coefficient | 0.53 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Non Operating Income Net Other
Most indicators from Supernus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 21st of May 2024, Issuance Of Capital Stock is likely to grow to about 8.4 M, while Selling General Administrative is likely to drop about 73.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 23.4M | 7.1M | 2.4M | 2.3M | Depreciation And Amortization | 34.0M | 82.6M | 84.9M | 89.1M |
Supernus Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Supernus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Supernus Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 53.8M | 53.7M | 54.4M | 61.7M | 55.5M | 42.6M | |
Total Assets | 1.2B | 1.5B | 1.7B | 1.7B | 1.4B | 1.5B | |
Short Long Term Debt Total | 375.6M | 390.3M | 420.6M | 438.0M | 41.5M | 39.5M | |
Other Current Liab | 3.2M | 40.0M | 65.0M | 139.8M | 279.9M | 293.9M | |
Total Current Liabilities | 160.6M | 245.1M | 315.4M | 688.0M | 290.2M | 154.7M | |
Total Stockholder Equity | 595.4M | 744.9M | 815.9M | 886.2M | 921.5M | 967.6M | |
Property Plant And Equipment Net | 38.3M | 37.8M | 17.0M | 15.2M | 42.5M | 44.7M | |
Net Debt | 194.2M | 101.7M | 217.1M | 344.8M | (33.5M) | (31.9M) | |
Retained Earnings | 199.5M | 326.5M | 379.9M | 481.2M | 482.6M | 506.7M | |
Accounts Payable | 10.1M | 78.9M | 117.7M | 96.3M | 2.0M | 1.9M | |
Cash | 181.4M | 288.6M | 203.4M | 93.1M | 75.1M | 116.1M | |
Non Current Assets Total | 687.6M | 873.7M | 1.1B | 968.4M | 915.9M | 961.7M | |
Non Currrent Assets Other | 615K | 8.0M | (36.1M) | (10.0M) | 8.5M | 8.9M | |
Cash And Short Term Investments | 347.1M | 422.5M | 339.7M | 461.3M | 254.9M | 201.2M | |
Net Receivables | 87.3M | 140.9M | 148.9M | 165.5M | 144.2M | 151.4M | |
Common Stock Total Equity | 51K | 52K | 53K | 54K | 62.1K | 40.8K | |
Short Term Investments | 165.7M | 133.9M | 136.2M | 368.2M | 179.8M | 98.1M | |
Liabilities And Stockholders Equity | 1.2B | 1.5B | 1.7B | 1.7B | 1.4B | 1.5B | |
Non Current Liabilities Total | 404.3M | 514.1M | 557.9M | 128.3M | 197.3M | 179.2M | |
Inventory | 26.6M | 48.3M | 86.0M | 91.5M | 77.4M | 81.3M | |
Other Current Assets | 11.6M | 18.7M | 27.0M | 15.8M | 16.7M | 8.5M | |
Other Stockholder Equity | 388.4M | 409.3M | 434.3M | 408.1M | 439.5M | 279.8M | |
Total Liab | 564.9M | 759.2M | 873.3M | 816.3M | 487.5M | 333.9M | |
Property Plant And Equipment Gross | 38.3M | 37.8M | 33.4M | 28.2M | 28.9M | 30.4M | |
Total Current Assets | 472.6M | 630.4M | 601.6M | 734.2M | 493.1M | 305.3M | |
Accumulated Other Comprehensive Income | 7.4M | 9.0M | 1.5M | (3.2M) | (593K) | (563.4K) | |
Intangible Assets | 24.8M | 442.3M | 784.7M | 702.5M | 599.9M | 629.9M | |
Common Stock | 51K | 52K | 53K | 54K | 55K | 42.0K | |
Other Liab | 28.7M | 123.8M | 137.4M | 92.3M | 106.2M | 111.5M | |
Current Deferred Revenue | 144.4M | 122.4M | 126.2M | 49.8M | 1.0 | 0.95 | |
Other Assets | 32.7M | 259.7M | 13.9M | 10.9M | 12.5M | 11.9M | |
Long Term Debt | 329.5M | 345.2M | 361.8M | 379.3M | 436.1M | 457.9M | |
Short Term Debt | 2.8M | 3.8M | 6.5M | 402.0M | 8.3M | 7.9M | |
Property Plant Equipment | 17.1M | 37.8M | 52.3M | 44.1M | 50.7M | 53.2M | |
Net Tangible Assets | 570.6M | 302.6M | (86.4M) | 66.7M | 76.7M | 72.9M | |
Good Will | 24.8M | 77.9M | 117.5M | 117.0M | 134.6M | 141.3M | |
Retained Earnings Total Equity | 199.5M | 326.5M | 379.9M | 481.2M | 553.4M | 581.1M | |
Capital Surpluse | 388.4M | 409.3M | 434.3M | 408.1M | 469.3M | 352.1M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Supernus Stock analysis
When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (0.29) | Revenue Per Share 10.933 | Quarterly Revenue Growth (0.07) | Return On Assets 0.0023 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.